Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is —OH or —OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

The application relates to a compound of Formula (I′) or (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I′) or (I), and a method of treating or preventing a disease in which SSAO plays a role.

Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

A fluorine-containing ether compound represented by a formula (1) shown below.

R.sup.1—(O(CH.sub.2).sub.a).sub.b-[A]-[B]—O—CH.sub.2—R.sup.2—CH.sub.2—R.sup.3  (1)

(In the formula (1), R.sup.1 is an alkyl group which may have a substituent, or an organic group having at least one double bond or triple bond. Further, a represents an integer of 2 to 4, and b is 0 or 1. [A] is represented by a formula (2): —(OCH.sub.2CH(OH)CH.sub.2).sub.c— (wherein c is 1 or 2). [B] is represented by a formula (3): —(O(CH.sub.2).sub.eCH(OH)CH.sub.2).sub.d— (wherein d is 0 or 1, and e represents an integer of 2 to 4). However, the sum of c in the formula (2) and d in the formula (3) is 2. R.sup.2 is a perfluoropolyether chain. R.sup.3 is represented by a formula (4): —(OCH.sub.2CH(OH)CH.sub.2).sub.2—O—CH.sub.2(CH.sub.2).sub.fOH (wherein f represents an integer of 2 to 5).

A fluorine-containing ether compound represented by a formula (1) shown below.

R.sup.1—(O(CH.sub.2).sub.a).sub.b-[A]-[B]—O—CH.sub.2—R.sup.2—CH.sub.2—R.sup.3  (1)

(In the formula (1), R.sup.1 is an alkyl group which may have a substituent, or an organic group having at least one double bond or triple bond. Further, a represents an integer of 2 to 4, and b is 0 or 1. [A] is represented by a formula (2): —(OCH.sub.2CH(OH)CH.sub.2).sub.c— (wherein c is 1 or 2). [B] is represented by a formula (3): —(O(CH.sub.2).sub.eCH(OH)CH.sub.2).sub.d— (wherein d is 0 or 1, and e represents an integer of 2 to 4). However, the sum of c in the formula (2) and d in the formula (3) is 2. R.sup.2 is a perfluoropolyether chain. R.sup.3 is represented by a formula (4): —(OCH.sub.2CH(OH)CH.sub.2).sub.2—O—CH.sub.2(CH.sub.2).sub.fOH (wherein f represents an integer of 2 to 5).

An actinic ray-sensitive or radiation-sensitive resin composition contains a compound that generates an acid upon irradiation with actinic rays or radiation and a resin whose polarity increases by the action of an acid, in which the compound is represented by a specific General Formula (X).

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.

The present inventors found cyclic peptide compounds that interact with Ras, and non-natural amino acids useful for the production of the cyclic peptide compounds. The inventors also found that the cyclic peptide compounds inhibit the binding between Ras and SOS. In addition, the inventors found specific non-natural amino acids contained in the cyclic peptide compounds and methods for production thereof.

The present inventors found cyclic peptide compounds that interact with Ras, and non-natural amino acids useful for the production of the cyclic peptide compounds. The inventors also found that the cyclic peptide compounds inhibit the binding between Ras and SOS. In addition, the inventors found specific non-natural amino acids contained in the cyclic peptide compounds and methods for production thereof.